Evotec Reports H1 Loss; Confirms FY13 Outlook
HAMBURG (dpa-AFX) - Evotec AG (EVOTF.PK, EVTCY.PK), a provider of drug discovery and development services to pharma and biotech companies, Thursday reported a loss for the first half of the year, reflecting lower revenues and higher expenses. The company confirmed its full-year revenue guidance.
For the six-month period, the company reported net loss of 4.5 million euros or 0.04 per share, compared with net income of 1.6 million euros or 0.01 per share.
Revenues for the period decreased to 36.9 million euros, from prior year's 42.04 million euros. Revenues excluding milestones, upfronts and licenses were up 6 percent.
Total operating expenses increased to 14.9 million euros, from 13.4 million euros a year ago.
For the full-year, the company confirmed its revenue outlook and expects it to grow between 90 million euros and 100 million euros.
Copyright RTT News/dpa-AFX